<table id="id_704c226b-8d5a-4758-8786-b2b8976bf4d5" width="431" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col width="44.3%"></col>
<col width="55.7%"></col>
<tbody>
<tr id="id_a7502e3c-5898-4da5-bd0e-e98b55c14294">
<td align="left" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">Interacting Drug</content>
</td>
<td align="left" stylecode="Lrule Botrule" valign="top">
<content stylecode="bold">Interaction</content>
</td>
</tr>
<tr id="id_acac3b40-56cd-4ff1-94fb-f46a19f47746">
<td align="left" stylecode="Botrule Rrule" valign="top">Drugs known to prolong QT interval (e.g., Class IA and Class III antiarrhythmic agents).</td>
<td align="left" stylecode="Lrule Botrule" valign="top">Quinine sulfate prolongs QT interval, ECG abnormalities including QT prolongation and torsade de pointes. Avoid concomitant use (<linkhtml href="#i4i_section_id_045c4f56-bc17-4289-afe7-e4cfc8266352">5.3</linkhtml>).</td>
</tr>
<tr id="id_61305ed4-4cb3-4ee7-98d0-9834eaf54a7c">
<td align="left" stylecode="Botrule Rrule" valign="top">Other antimalarials (e.g., halofantrine, mefloquine).</td>
<td align="left" stylecode="Lrule Botrule" valign="top">ECG abnormalities including QT prolongation. Avoid concomitant use (<linkhtml href="#i4i_section_id_045c4f56-bc17-4289-afe7-e4cfc8266352">5.3</linkhtml>, <linkhtml href="#i4i_section_id_f1fef4b3-69ed-4800-a0a8-adbb376895b4">7.2</linkhtml>).</td>
</tr>
<tr id="id_cf05484f-bf42-4e62-a589-3b951d69d8ac">
<td align="left" stylecode="Botrule Rrule" valign="top">CYP3A4 inducers or inhibitors</td>
<td align="left" stylecode="Lrule Botrule" valign="top">Alteration in plasma quinine concentration. Monitor for lack of efficacy or increased adverse events of quinine (<linkhtml href="#i4i_section_id_ccff0fde-c21d-4250-a838-691d09fae712">7.1</linkhtml>).</td>
</tr>
<tr id="id_bb6543d1-d146-4ffa-ad9f-02bbbb5d7b90">
<td align="left" stylecode="Botrule Rrule" valign="top">CYP3A4 and CYP2D6 substrates</td>
<td align="left" stylecode="Lrule Botrule" valign="top">Quinine is an inhibitor of CYP3A4 and CYP2D6. Monitor for lack of efficacy or increased adverse events of the coadministered drug (<linkhtml href="#i4i_section_id_f1fef4b3-69ed-4800-a0a8-adbb376895b4">7.2</linkhtml>).</td>
</tr>
<tr id="id_92f0fb5f-84da-41ad-b523-ce98d549d1a7">
<td align="left" stylecode="Rrule" valign="top">Digoxin</td>
<td align="left" stylecode="Botrule" valign="top">Increased digoxin plasma concentration (<linkhtml href="#i4i_section_id_91eb747b-35e0-4097-bb4d-a62b09e9dccd">5.8</linkhtml>, <linkhtml href="#i4i_section_id_ccff0fde-c21d-4250-a838-691d09fae712">7.1</linkhtml>).</td>
</tr>
</tbody>
</table>